May 23 saw the CEMA Medical Technology Promotion Working Committee Founding Conference & National Science and Technology Program Policy Interpretation and Research Findings Commercialization Press Conference held in Beijing. At the conference, the members of the Medical Technology Promotion Council were elected. Comrade Li Jianhua was elected as the first-term chairman, comrade Wang Shuqiang as the first-term executive vice chairman and secretary general, Wang Fan, Du Guanhua and Xi Tingfei as vice chairmen. At the National Science and Technology Program Policy Interpretation and Research Findings Commercialization Press Conference Convened concurrently, officials from the Development Research Center of the State Council, the Ministry of Science and Technology and the National Health and Family Planning Committee reported and interpreted the development strategies of national health industry, national science and technology policies and current hot issues. The strategic cooperation signing ceremony between the Medical Technology Promotion Working Committee and seven enterprises including Boyalife Group was also held for joint development of strategic emerging industries in biopharmaceuticals.
The Medical Technology Promotion Working Committee announced at the conference that Wu Jieping Medical Foundation had established the Special Fund for Clinical Translation and Application of Stem Cell Treatment Technology to fund scientific research projects jointly applied by nationwide public hospitals and Boyalife Group. Mainly sponsoring stem cell clinical translation and application projects in the treatment of infertility, gynecological oncology, thalassemia and other diseases, this fund will have an important effect on the stem cell industry and Chinese research and treatment of major diseases.
Recent years have seen stem cell research and application becoming a new approach and a new hope for regenerative repair and treatment of such major diseases as cardiovascular disease, nervous system disease and liver system disease, and a hotspot of international competition in life science and medicine. This special fund has been jointly established by the Medical Technology Promotion Working Committee and Wu Jieping Medical Foundation to further accelerate the clinical translation and application of stem cell technologies, enhance the sustainable innovation ability of Chinese biopharmaceuticals and improve people’s health. Winning great support of ministries and commissions, the special fund will select research undertakers and research project leaders through just, fair and transparent bidding.
For researchers of nationwide Public Hospitals and Boyalife Group, key support from this special fund will effectively integrate quality research resources, push forward the clinical application of stem cell treatment technologies in infertility, gynecological oncology, thalassemia and other diseases, and exert a positive and far-reaching impact on the research and treatment of major difficult and complicated diseases.
In the report titled “The Past, Present and Future of Stem Cell Technologies”, Dr. Xu Xiaochun, chairperson of Boyalife Group and visiting professor of IMM PKU, shared the hot topics of stem cell, including the 8 internationally approved stem cell treatment technologies, the greatly increasing application of autotransplantation in the international scene and China’s little importance attached to newborn stem cell (the United States has a stem cell preservation rate as high as 10.7%; Japan and Taiwan 15% to 20%; Mainland China less than 1%). As an industry trend setter, Boyalife Group has been unremittingly committed to the sound development of stem cell industry. Undertaking the researches of the Special Fund for Clinical Translation and Application of Stem Cell Treatment Technology with nationwide public hospitals, Boyalife Group will change China’s treatment ideas and methods of infertility, gynecological oncology, thalassemia and other diseases, facilitate new more effective treatment measures than chemotherapy, drug therapy and other conventional therapies, and truly and successfully apply technologies in health.
Since its establishment in 2009, Boyalife Group has been working closely with multiple clinical organizations, promoting the application of stem cell technologies and bringing hope to numerous patients. Collaborating with the Affiliated Hospital of Nanjing University and the Affiliated Hospital of Jiangsu University from 2010 to 2014, Boyalife Group had unfolded clinical research on autoimmune diseases with MSC and saved a great number of patients. Last year, the Clinical Cooperation Project of Autoimmune diseases with Stem Cell Treatment between Boyalife Group and the Affiliated Hospital of Nanjing University won the First Class Award of Jiangsu Province Scientific and Technological Progress Award.